Key stats
About Putnam BioRevolution ETF
Home page
Inception date
Sep 29, 2022
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Putnam Investment Management LLC
Distributor
Franklin Distributors LLC
ISIN
US7467298052
SYNB holds a high conviction portfolio that provides exposure to bio revolution, which involves technological advancements in the biological and life sciences that contribute to transforming the economy. The fund primarily invests in (i) technology enablers that provide the materials, equipment, and knowledge to enable biological production, (ii) disruptive biotech or synthetic bio companies, and (iii) other firms positioned to benefit from the theme. The funds exposure goes beyond healthcare, as it may also invest in other sectors that are likely to be positively impacted, such as consumer discretionary, consumer staples, materials, and agriculture. SYNB's portfolio typically comprises growth stocks. In selecting stocks, the fund manager considers valuation, financial strength, growth potential, industry position, projected future earnings, cash flows, and dividends.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Process Industries
Stocks96.94%
Health Technology52.68%
Process Industries23.84%
Consumer Non-Durables6.32%
Electronic Technology4.46%
Technology Services3.93%
Commercial Services3.53%
Distribution Services2.18%
Bonds, Cash & Other3.06%
Mutual fund3.07%
Cash−0.00%
Stock breakdown by region
North America70.75%
Europe29.25%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
SYNB invests in stocks. The fund's major sectors are Health Technology, with 52.69% stocks, and Process Industries, with 23.84% of the basket. The assets are mostly located in the North America region.
SYNB top holdings are Thermo Fisher Scientific Inc. and Corteva Inc, occupying 8.12% and 6.05% of the portfolio correspondingly.
SYNB last dividends amounted to 0.21 USD. The year before, the issuer paid 0.02 USD in dividends, which shows a 90.14% increase.
SYNB assets under management is 5.32 M USD. It's risen 4.65% over the last month.
SYNB fund flows account for 0.00 USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, SYNB pays dividends to its holders with the dividend yield of 0.00%. The last dividend (Dec 9, 2024) amounted to 0.21 USD. The dividends are paid annually.
SYNB shares are issued by Franklin Resources, Inc. under the brand Putnam. The ETF was launched on Sep 29, 2022, and its management style is Active.
SYNB expense ratio is 0.71% meaning you'd have to pay 0.71% of your investment to help manage the fund.
SYNB follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
SYNB invests in stocks.
SYNB price has risen by 4.17% over the last month, and its yearly performance shows a −6.52% decrease. See more dynamics on SYNB price chart.
NAV returns, another gauge of an ETF dynamics, showed a 9.75% increase in three-month performance and has decreased by −6.93% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 9.75% increase in three-month performance and has decreased by −6.93% in a year.
SYNB trades at a premium (0.09%) meaning the ETF is trading at a higher price than the calculated NAV.